Neoadjuvant SHR-1210 Plus Apatinib for Resectable Stage III-IV Acral Melanoma
Condition: Acral Melanoma Intervention: Drug: SHR-1210+Apatinib Sponsor: Di Wu Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials